DWA
PETX

Dorsey Wright & Associates’s Aratana Therapeutics, Inc. PETX Stock Holding History

Dorsey Wright & Associates’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,366
Closed -$15K – 352
2018
Q4 		$15K Buy
+2,366
New +$14.4K ﹤0.01% 206

Other funds holding PETX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return

Dorsey Wright & Associates's PETX Position: Q1 2019 in Review

Dorsey Wright & Associates sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2019, closing a stake of 2,366 shares — an estimated $15K sold.

Dorsey Wright & Associates first reported a position in PETX in Q4 2018 and held it in 1 quarter. The position peaked at $15K in Q4 2018. 104 funds tracked by Wall St. Rank hold PETX as of Q1 2019.

  • Dorsey Wright & Associates reported no remaining Aratana Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Dorsey Wright & Associates sold 2,366 Aratana Therapeutics, Inc. shares in Q1 2019, an estimated $15K.
  • Dorsey Wright & Associates first reported a position in Aratana Therapeutics, Inc. in Q4 2018 and held it in 1 quarter.
  • Dorsey Wright & Associates's Aratana Therapeutics, Inc. position peaked at $15K in Q4 2018.
  • 104 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2019.

Based on Dorsey Wright & Associates's 13F filing for Q1 2019, filed 4 Apr 2019.